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Background:
Bronchiolitis is one of the most common diseases requiring hospitalization in children 1-24
months of age, but presently treatment is primarily supportive. High flow nasal cannula is a
newer method of oxygen delivery pediatric hospitals have been rapidly adopting to treat
respiratory insufficiency caused by viral bronchiolitis.
Objectives/Goal:
We sought to compare resource utilization, including cost, length of stay (LOS), and
readmission among children who were treated with HFNC versus those who were not.
Methods/Design:
In this cross-sectional, multicenter study, we obtained clinical and resource utilization data from
the Pediatric Health Information System (PHIS) database for otherwise healthy children 1 to 24
months of age admitted for bronchiolitis. We assessed treatment with HFNC based on a
combination of billing codes and reviewed 1,105 charts at two centers to determine the
accuracy of these codes. We compared costs, LOS, and readmission rates between those who
received HFNC and those who did not.
Results:
The PHIS database codes demonstrated sensitivity of 90.4% and specificity of 99.3% to detect
encounters in which HFNC use was verified by chart review. Children treated with HFNC had
longer LOS (44.5 vs. 31.2 hours; p<0.001), greater total costs ($5460 vs. $3540; p<0.001), and
greater daily costs ($3,017 vs. $2,750; p<0.001). Those treated with HFNC were less likely to be
readmitted by 3 and 7 days (p<0.001), but by 14 days readmission rates were similar in the two
groups.

Conclusions:
Children with bronchiolitis treated with HFNC required more intense resource utilization (longer
LOS and greater costs) compared to those not treated with HFNC. Cost remained greater after
accounting for their increased LOS. Greater understanding of the criteria used to place children
on HFNC is needed to better assess its value.

